Fundraising FoxVersant Venture Capital — 2016 Investments
1 investments dated 2016 · listed companies and verified rows first · show all
CRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology.
BiotechDeep TechHealthtechZug, CH
Emmanuelle Charpentier(Founder)Samarth Kulkarni(Chief Executive Officer and Chairman of the Board)inJames R. Kasinger(General Counsel and Secretary)inStephen Kennedy(Head of Technical Operations)inMegan Wherry Menner(Head of Human Resources)inNaimish Patel(Chief Medical Officer)in
Board seatBradley BolzonThomas Woiwode· per SEC Form D · $35M raise · filed Nov 2016
Co-investorsAvoro Capital AdvisorsCLI VenturesKhosla VenturesNew Enterprise Associates (NEA)SR One Capital ManagementVersant Ventures+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.